378 related articles for article (PubMed ID: 26168222)
1. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.
Meyer M; Garron T; Lubaki NM; Mire CE; Fenton KA; Klages C; Olinger GG; Geisbert TW; Collins PL; Bukreyev A
J Clin Invest; 2015 Aug; 125(8):3241-55. PubMed ID: 26168222
[TBL] [Abstract][Full Text] [Related]
2. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.
DiNapoli JM; Yang L; Samal SK; Murphy BR; Collins PL; Bukreyev A
Vaccine; 2010 Dec; 29(1):17-25. PubMed ID: 21034822
[TBL] [Abstract][Full Text] [Related]
3. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.
Bukreyev AA; Dinapoli JM; Yang L; Murphy BR; Collins PL
Virology; 2010 Apr; 399(2):290-8. PubMed ID: 20129638
[TBL] [Abstract][Full Text] [Related]
4. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
Bukreyev A; Yang L; Zaki SR; Shieh WJ; Rollin PE; Murphy BR; Collins PL; Sanchez A
J Virol; 2006 Mar; 80(5):2267-79. PubMed ID: 16474134
[TBL] [Abstract][Full Text] [Related]
5. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
[TBL] [Abstract][Full Text] [Related]
6. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals.
Yang L; Sanchez A; Ward JM; Murphy BR; Collins PL; Bukreyev A
Virology; 2008 Aug; 377(2):255-64. PubMed ID: 18570964
[TBL] [Abstract][Full Text] [Related]
7. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.
Herbert AS; Kuehne AI; Barth JF; Ortiz RA; Nichols DK; Zak SE; Stonier SW; Muhammad MA; Bakken RR; Prugar LI; Olinger GG; Groebner JL; Lee JS; Pratt WD; Custer M; Kamrud KI; Smith JF; Hart MK; Dye JM
J Virol; 2013 May; 87(9):4952-64. PubMed ID: 23408633
[TBL] [Abstract][Full Text] [Related]
8. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
9. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
[TBL] [Abstract][Full Text] [Related]
10. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
J Virol; 2017 May; 91(10):. PubMed ID: 28250127
[TBL] [Abstract][Full Text] [Related]
11. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
13. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.
Furuyama W; Shifflett K; Pinski AN; Griffin AJ; Feldmann F; Okumura A; Gourdine T; Jankeel A; Lovaglio J; Hanley PW; Thomas T; Clancy CS; Messaoudi I; O'Donnell KL; Marzi A
mBio; 2022 Feb; 13(1):e0337921. PubMed ID: 35012339
[TBL] [Abstract][Full Text] [Related]
14. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity.
Martins KAO; Cooper CL; Stronsky SM; Norris SLW; Kwilas SA; Steffens JT; Benko JG; van Tongeren SA; Bavari S
EBioMedicine; 2016 Jan; 3():67-78. PubMed ID: 26870818
[TBL] [Abstract][Full Text] [Related]
16. Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans.
Vu H; Shulenin S; Grolla A; Audet J; He S; Kobinger G; Unfer RC; Warfield KL; Aman MJ; Holtsberg FW
Antiviral Res; 2016 Feb; 126():55-61. PubMed ID: 26681387
[TBL] [Abstract][Full Text] [Related]
17. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.
Hensley LE; Mulangu S; Asiedu C; Johnson J; Honko AN; Stanley D; Fabozzi G; Nichol ST; Ksiazek TG; Rollin PE; Wahl-Jensen V; Bailey M; Jahrling PB; Roederer M; Koup RA; Sullivan NJ
PLoS Pathog; 2010 May; 6(5):e1000904. PubMed ID: 20502688
[TBL] [Abstract][Full Text] [Related]
18. A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection.
Choi JH; Jonsson-Schmunk K; Qiu X; Shedlock DJ; Strong J; Xu JX; Michie KL; Audet J; Fernando L; Myers MJ; Weiner D; Bajrovic I; Tran LQ; Wong G; Bello A; Kobinger GP; Schafer SC; Croyle MA
Mol Pharm; 2015 Aug; 12(8):2712-31. PubMed ID: 25363619
[TBL] [Abstract][Full Text] [Related]
19. Evaluation in nonhuman primates of vaccines against Ebola virus.
Geisbert TW; Pushko P; Anderson K; Smith J; Davis KJ; Jahrling PB
Emerg Infect Dis; 2002 May; 8(5):503-7. PubMed ID: 11996686
[TBL] [Abstract][Full Text] [Related]
20. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]